Literature DB >> 27393117

Development of the multiple sclerosis (MS) early mobility impairment questionnaire (EMIQ).

Tjalf Ziemssen1, Glenn Phillips2, Ruchit Shah3, Adam Mathias4, Catherine Foley4, Cheryl Coon4, Rohini Sen4, Andrew Lee5, Sonalee Agarwal2.   

Abstract

The Early Mobility Impairment Questionnaire (EMIQ) was developed to facilitate early identification of mobility impairments in multiple sclerosis (MS) patients. We describe the initial development of the EMIQ with a focus on the psychometric evaluation of the questionnaire using classical and item response theory methods. The initial 20-item EMIQ was constructed by clinical specialists and qualitatively tested among people with MS and physicians via cognitive interviews. Data from an observational study was used to make additional updates to the instrument based on exploratory factor analysis (EFA) and item response theory (IRT) analysis, and psychometric analyses were performed to evaluate the reliability and validity of the final instrument's scores and screening properties (i.e., sensitivity and specificity). Based on qualitative interview analyses, a revised 15-item EMIQ was included in the observational study. EFA, IRT and item-to-item correlation analyses revealed redundant items which were removed leading to the final nine-item EMIQ. The nine-item EMIQ performed well with respect to: test-retest reliability (ICC = 0.858); internal consistency (α = 0.893); convergent validity; and known-groups methods for construct validity. A cut-point of 41 on the 0-to-100 scale resulted in sufficient sensitivity and specificity statistics for viably identifying patients with mobility impairment. The EMIQ is a content valid and psychometrically sound instrument for capturing MS patients' experience with mobility impairments in a clinical practice setting. Additional research is suggested to further confirm the EMIQ's screening properties over time.

Entities:  

Keywords:  EMIQ; MS; Multiple sclerosis; Screener

Mesh:

Year:  2016        PMID: 27393117     DOI: 10.1007/s00415-016-8210-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  21 in total

1.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Authors:  L D Jacobs; R W Beck; J H Simon; R P Kinkel; C M Brownscheidle; T J Murray; N A Simonian; P J Slasor; A W Sandrock
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

2.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

3.  Index for rating diagnostic tests.

Authors:  W J YOUDEN
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

4.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

Authors:  G Comi; M Filippi; F Barkhof; L Durelli; G Edan; O Fernández; H Hartung; P Seeldrayers; P S Sørensen; M Rovaris; V Martinelli; O R Hommes
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

5.  Gait and balance impairment in early multiple sclerosis in the absence of clinical disability.

Authors:  C L Martin; B A Phillips; T J Kilpatrick; H Butzkueven; N Tubridy; E McDonald; M P Galea
Journal:  Mult Scler       Date:  2006-10       Impact factor: 6.312

6.  Validity of performance scales for disability assessment in multiple sclerosis.

Authors:  R A Marrie; M Goldman
Journal:  Mult Scler       Date:  2007-07-10       Impact factor: 6.312

7.  Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors.

Authors:  Ivonne Krause; Simone Kern; Antje Horntrich; Tjalf Ziemssen
Journal:  Mult Scler       Date:  2013-05-01       Impact factor: 6.312

8.  Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.

Authors:  Ludwig Kappos; Mark S Freedman; Chris H Polman; Gilles Edan; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Frederik Barkhof; Ernst-Wilhelm Radü; Carola Metzig; Lars Bauer; Vivian Lanius; Rupert Sandbrink; Christoph Pohl
Journal:  Lancet Neurol       Date:  2009-09-10       Impact factor: 44.182

Review 9.  Incidence and prevalence of multiple sclerosis in Europe: a systematic review.

Authors:  Elaine Kingwell; James J Marriott; Nathalie Jetté; Tamara Pringsheim; Naila Makhani; Sarah A Morrow; John D Fisk; Charity Evans; Sarah Gabrielle Béland; Sophie Kulaga; Jonathan Dykeman; Christina Wolfson; Marcus W Koch; Ruth Ann Marrie
Journal:  BMC Neurol       Date:  2013-09-26       Impact factor: 2.474

10.  A personalized, intense physical rehabilitation program improves walking in people with multiple sclerosis presenting with different levels of disability: a retrospective cohort.

Authors:  Alon Kalron; Dalia Nitzani; David Magalashvili; Mark Dolev; Shay Menascu; Yael Stern; Uri Rosenblum; Diana Pasitselsky; Lior Frid; Gabi Zeilig; Caroline Barmatz; Uri Givon; Anat Achiron
Journal:  BMC Neurol       Date:  2015-03-04       Impact factor: 2.474

View more
  4 in total

1.  Data Collection in Multiple Sclerosis: The MSDS Approach.

Authors:  Tjalf Ziemssen; Raimar Kern; Isabel Voigt; Rocco Haase
Journal:  Front Neurol       Date:  2020-06-16       Impact factor: 4.003

2.  Differential neurodegenerative phenotypes are associated with heterogeneous voiding dysfunction in a coronavirus-induced model of multiple sclerosis.

Authors:  Sanghee Lee; Balachandar Nedumaran; Joseph Hypolite; Brian Caldwell; Michael C Rudolph; Anna P Malykhina
Journal:  Sci Rep       Date:  2019-07-26       Impact factor: 4.379

Review 3.  Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting.

Authors:  Philipp Albrecht; Ingrid Kristine Bjørnå; David Brassat; Rachel Farrell; Peter Feys; Jeremy Hobart; Raymond Hupperts; Michael Linnebank; Jožef Magdič; Celia Oreja-Guevara; Carlo Pozzilli; Antonio Vasco Salgado; Tjalf Ziemssen
Journal:  Ther Adv Neurol Disord       Date:  2018-10-05       Impact factor: 6.570

4.  The Dresden Protocol for Multidimensional Walking Assessment (DMWA) in Clinical Practice.

Authors:  Katrin Trentzsch; Marie Luise Weidemann; Charlotte Torp; Hernan Inojosa; Maria Scholz; Rocco Haase; Dirk Schriefer; Katja Akgün; Tjalf Ziemssen
Journal:  Front Neurosci       Date:  2020-10-26       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.